Palivizumab was the only approved therapy to prevent severe RSV disease in infants and young children until the approval of nirsevimab in 2023.

Glaxosmithkline, which has major operations in Montgomery County, is set to receive a major settlement, writes Anthony O. Goriainoff for the Wall Street Journal. The pharmaceutical powerhouse will ...